Social Media Ideas for The New England Journal Of Medicine

The epicenter of a crisis in modern medical care

Introducing - Intention to Treat: Money and Misdiagnosis

Intention to Treat: The Race Equation is a new series from the New England Journal of Medicine, investigates how race-specific diagnostic tools harm Black patients and contribute t...

Good News on the HIV Front

By MIKE MAGEE In a 1996  JAMA editorial Nobel Laureate Joshua Lederberg MD wrote “Our fight with microbes is far from over …odds are tipped in their favor…they outnumber us a billi...

Here’s the latest.

Here’s the latest.

Unveiling Reporting & Representation of Race and Ethnicity in Acute Interventional Neurology Trials: A Systematic Re...

Congratulations on your new publication! Congratulations to Hector David Meza Comparan, Luciola Frota, Michael Mathelier, Carolina Maciel and Katharina Busl on the publication of “...

Near death at sea, ‘sea change' in care: Survivor spotlights shift in fatty liver disease

When Jerry Rosenberg boarded a cruise to Bermuda in April 2017, he was not expecting to return to the U.S. in an air ambulance a few days later.He spent the rest of the month in an...

Top Doctors: Heart-to-Heart

Heart disease has been the leading cause of death in the United States for more than a century—but not in Minnesota, where local Top Doctors sit on the cutting edge of transformati...

New ELANE Mutations Trigger Neutrophil Trap Formation

In a groundbreaking study published this month, researchers have uncovered novel mutations in the neutrophil elastase gene (ELANE) that contribute to the pathophysiology of cyclic...

Q&A: New JAMA resource shows ‘labor of love’ behind clinical trials

JAMA Network announced a new resource called JAMA+ Trials that is “designed to elevate the visibility, accessibility and understanding of trusted clinical trial research across med...

Another covid jabs study underpinned by flawed science

MEDICAL journals have become adept at producing studies that generate headlines while concealing their weaknesses in the supplementary material. Few examples illustrate this better...

Igniting Discovery: Cardiac research with a personal touch

HN Summary • Sunnybrook Health Sciences Centre researchers are advancing personalized cardiac care through international clinical trials evaluating new minimally invasive procedure...

New Math Method Inflates Alzheimer’s Drug Success by 29x

A critical research lette exposes severe flaws in "quantile aggregation", a statistical technique recently used by pharmaceutical researchers to evaluate the drug donanemab.

<![CDATA[Pharmaceutical Executive Daily: The Medicare GLP-1 Bridge]]>

<![CDATA[The New Capital of Care in Rare Disease]]>

Major international study on respiratory support in critical illness

HN Summary • A major international study led by Scarborough Health Network found that CPAP, high-flow nasal cannula and bilevel non-invasive ventilation can reduce the need for inv...

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) di...

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (I...

3 pharma conflicts of interest hiding in plain sight

1. Medical journals are going the way of newspapers, as in “extinct” Who remembers newspapers? Pre-smartphone compendiums of world and local events on paper that required reporters...

Connecticut Updates its Medical Orders for Life-Sustaining Treatment Program

Alternative first-line treatment proves effective for persistent atrial fibrillation

HN Summary • VCHRI researcher Dr. Jason Andrade’s work is the first to prove the efficacy of catheter ablation as an initial treatment for patients with advanced forms of AFib. • H...

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies drivi...

Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's dis...

Edgewise heart drug passes key trial test

Still, the results leave somewhat unclear how different the company’s drug is than marketed hypertrophic cardiomyopathy medicines from Bristol Myers Squibb and Cytokinetics.

ICU Pneumonia Mortality Rates: 37%-60% in Middle-Income vs. 16%-26% in High-Income Countries

A groundbreaking systematic review published in NEJM Evidence and coordinated by the D’Or Institute for Research and Education (IDOR) reveals stark disparities in outcomes for adul...

Healthcare Economist Weekly Reader

FDA accepts 1st In Silico Drug Development Tool. Why GLP-1’s got more affordable. BALANCE after CMS GLP-1 decision. How to socialize scientific ideas in the age of AI. Mapping the...